Sensipar, Mimpara(cinacalcet)
Mimpara, Sensipar (cinacalcet) is a small molecule pharmaceutical. Cinacalcet was first approved as Sensipar on 2004-03-08. It is used to treat parathyroid neoplasms, primary hyperparathyroidism, and secondary hyperparathyroidism in the USA. It has been approved in Europe to treat hypercalcemia, hyperparathyroidism, parathyroid neoplasms, and secondary hyperparathyroidism. The pharmaceutical is active against extracellular calcium-sensing receptor. In addition, it is known to target metabotropic glutamate receptor 5.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Sensipar (generic drugs available since 2018-03-08)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cinacalcet hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SENSIPAR | Amgen | N-021688 RX | 2004-03-08 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
cinacalcet | ANDA | 2023-06-07 |
sensipar | New Drug Application | 2023-02-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
parathyroid neoplasms | — | D010282 | — |
primary hyperparathyroidism | EFO_0008519 | D049950 | E21.0 |
secondary hyperparathyroidism | EFO_1001173 | D006962 | — |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
---|---|
J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Secondary hyperparathyroidism | D006962 | EFO_1001173 | 2 | 9 | 12 | 14 | 3 | 37 | |
Chronic renal insufficiency | D051436 | N18 | 1 | 2 | 6 | 6 | — | 15 | |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 4 | 5 | 2 | 1 | 12 |
Primary hyperparathyroidism | D049950 | EFO_0008519 | E21.0 | — | 5 | 4 | 1 | 2 | 11 |
Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | 3 | 3 | 1 | 7 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 3 | 2 | — | 5 |
Parathyroid neoplasms | D010282 | — | — | 2 | 1 | — | 3 | ||
Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | 2 | — | 2 |
Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | 1 | 1 | — | 2 |
Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercalcemia | D006934 | E83.52 | 1 | 1 | 2 | — | — | 3 | |
Hypophosphatemia | D017674 | HP_0002148 | — | — | 1 | — | 1 | 2 | |
Kidney transplantation | D016030 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
Chronic kidney disease-mineral and bone disorder | D012080 | EFO_1001152 | N25.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 1 | — | — | — | 1 | 2 | ||
Familial hypophosphatemic rickets | D053098 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CINACALCET |
INN | cinacalcet |
Description | Cinacalcet is a secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group. It has a role as a calcimimetic and a P450 inhibitor. It is a member of naphthalenes, a secondary amino compound and a member of (trifluoromethyl)benzenes. |
Classification | Small molecule |
Drug class | calcium-sensing receptor (CaSR) agonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12 |
Identifiers
PDB | — |
CAS-ID | 226256-56-0 |
RxCUI | 407990 |
ChEMBL ID | CHEMBL1201284 |
ChEBI ID | 48390 |
PubChem CID | 156419 |
DrugBank | DB01012 |
UNII ID | UAZ6V7728S (ChemIDplus, GSRS) |
Target
Agency Approved
CASR
CASR
Organism
Homo sapiens
Gene name
CASR
Gene synonyms
GPRC2A, PCAR1
NCBI Gene ID
Protein name
extracellular calcium-sensing receptor
Protein synonyms
parathyroid Ca(2+)-sensing receptor 1, Parathyroid cell calcium-sensing receptor 1, PCaR1
Uniprot ID
Mouse ortholog
Casr (12374)
extracellular calcium-sensing receptor (Q9R1Y2)
Alternate
GRM5
GRM5
Variants
Clinical Variant
No data
Financial
Sensipar - Amgen
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,418 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
70,628 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more